BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioCon Limited Launches Haselmeier's Insulin Pen in India


11/22/2011 10:50:33 AM

Zurich, Switzerland, November 22, 2011 / B3C newswire / - Haselmeier has announced that Biocon, one of Asia’s premier biotechnology companies, has launched INSUPen® in India. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen®, for use with Biocon’s insulin and insulin analogues. The first launch of the INSUPen® has taken place with Biocon’s Basalog® and Insugen® insulins.

The INSUPen® is a reusable insulin pen based on Haselmeier’s popular i-pen technology. It is designed to be easy to use for the patient and provide accurate and reliable dosing. The INSUPen® is available in 3 attractive colors and is currently custom designed for use with both Basalog® and Insugen®, thus maximizing patient convenience.

The INSUPen® provides diabetic patients an attractive pen with user-friendly features at an affordable cost. Haselmeier is proud to work with Biocon, a premier biotechnology company, on this important program to develop and supply INSUPen®and we look forward to a long and successful partnership,” said Volker Wirth, Director Business Development & Marketing at Haselmeier.

Rakesh Bamzai, President, Marketing at Biocon added: “I am confident that INSUPen® will be a delight for patients and a value enhancer for all stakeholders.”

About Haselmeier GmbH

Haselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Company’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. For more information visit: www.Haselmeier.com

About Biocon Limited

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).

Contact

Haselmeier GmbH

Nadia Di Secli

Dufourstr. 32

CH-8008 Zürich

Switzerland

Tel.: + 41 44 250 52 40

n.secli@haselmeier.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES